Business / Industry Sectors
Sun Pharma defends Ranbaxy deal; rejects insider trading claims
23/04/2014
Chairman Israel Makov exudes confidence on fixing regulatory issues, integrating workforce

For the 29,000 employees across Sun Pharmaceutical Industries and Ranbaxy Laboratories, history was made recently, as the two companies sought to merge and create the country’s largest drug-maker.

 

Sun’s journey has only just begun as it sets out to integrate two cultures and deal with Ranbaxy’s legacy issues, involving regulatory woes in the US for its India-based plants.

Addressing the huge integration that lies ahead, Israel Makov, Sun Pharma’s Chairman, said: “We look at employees as an asset and not liability”. Sun would look to guide people, make them more accountable and introduce management systems, and motivate employees to increase productivity. He added. “Our eyes are focused on Sun….We are going to be Sun and we don’t have a megalomanical aspiration to be Teva or Facebook.” All Sun wants is to give shareholders a standard of profitable growth, he added.

 

Source: THE HINDU BUSINESSLINE

Image courtesy:  www.bing.com

 

 

Register your company in our INDEX OF COMPANIES

Have comments? Write to us | Send to a friend | Print |
Share |
ad
ad
ad
ad
ad
ad